There are currently 66 clinical trials in Tempe, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Celerion, Arizona State University, Celerion Inc. and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Vancomycin for Primary Sclerosing Cholangitis
NCT03710122
Recruiting
To find out if vancomycin is a safe and effective therapy for primary sclerosing cholangitis. Funding Source - FDA OOPD
Gender:
All
Ages:
Between 18 years and 76 years
Trial Updated:
04/17/2024
Locations: Arizona State University, Tempe, Arizona
Conditions: Primary Sclerosing Cholangitis
Register for Updates
A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
NCT05432583
Recruiting
This exploratory trial will have two parts. Part A is a dose escalation part and Part B is an expanded safety and dose evaluation part. Part A will focus on the safety evaluations, but vaccine-induced immune responses (specifically neutralizing antibodies) will also be analyzed to assess if there is a dose-response. Part B of the trial will expand the safety characterization for two dose levels of BNT163 selected based on Part A data and also enable a more comprehensive assessment of the impact... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
04/03/2024
Locations: Alliance for Multispecialty Research, LLC, Tempe, Arizona
Conditions: Genital Herpes Simplex Type 2
Register for Updates
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination
NCT06007183
Recruiting
The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of PXVX0317 in adult and adolescent participants and to evaluate PXVX0317 booster vaccine induced serum neutralizing antibody (SNA) response at 3, 4, or 5 years post-initial PXVX0317 vaccination.
Gender:
All
Ages:
Between 12 years and 67 years
Trial Updated:
03/26/2024
Locations: Alliance for Multispecialty Research, LLC, Tempe, Arizona
Conditions: Chikungunya Virus Infection
Register for Updates
Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders
NCT06321796
Recruiting
The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating patients with Pitt-Hopkins Syndrome (PTHS) and gastrointestinal problems (constipation, bloating, abdominal pain). MTT involves a combination of 10 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by 1 day of bowel cleanse using magnesium citrate, followed by 4 days of high dose MTP-101P with an antacid, followed by 12 weeks of a lower maintenance dose of MTP-101P with an antacid.
Gender:
All
Ages:
Between 5 years and 55 years
Trial Updated:
03/14/2024
Locations: Autism/Asperger's Research Group at Arizona State University, Tempe, Arizona
Conditions: Pitt Hopkins Syndrome
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Tempe, Arizona +1 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
The Electronic Medical Records and GEnomics (eMERGE) Network Genomic Risk Assessment
NCT05277116
Recruiting
The eMERGE Network embraces the opportunity to use new methods in genomic medicine, information science, and research participant engagement to identify people at very high risk for specific diseases and recommend individualized approaches to prevention and care. The investigators will conduct a prospective study, with diverse and underserved participants, across ten eMERGE study sites to evaluate clinical implementation of a Genome Informed Risk Assessment (GIRA) tool that combines genetic, fam... Read More
Gender:
All
Ages:
Between 3 years and 75 years
Trial Updated:
03/07/2024
Locations: Mountain Park Health Center, Tempe, Arizona
Conditions: Genetic Disease
Register for Updates
Episealer® Knee System IDE Clinical Study
NCT04000659
Recruiting
The study is a randomized, prospective, multicenter, controlled clinical trial of the Episealer Knee System. The Episealer Knee System is intended for subjects with up to two focal femoral knee chondral or osteochondral lesion that is causing pain and/or disability and requires surgical treatment.
Gender:
All
Ages:
Between 30 years and 70 years
Trial Updated:
03/05/2024
Locations: Physicians Research Group, Tempe, Arizona
Conditions: Degenerative Lesion of Articular Cartilage of Knee
Register for Updates
Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
NCT04549116
Recruiting
This is a multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority clinical study in women aged 35 to 42 years. This study will investigate the safety and efficacy of Progesterone-IBSA to support euploid embryo blastocyst implantation and early pregnancy after frozen embryo transfer (FET) in a modified natural cycle as a treatment for infertile women. Subjects will be randomized to receive either active Progesterone-IBSA or Crinone 8% for luteal and early pregnancy... Read More
Gender:
Female
Ages:
Between 35 years and 42 years
Trial Updated:
03/04/2024
Locations: The Fertility Treatment Center, LLC, Tempe, Arizona
Conditions: Infertility
Register for Updates
A Study of EDG-7500 in Healthy Adults
NCT06011317
Recruiting
The purposes of this Phase 1 study of EDG-7500 are to: Learn about the safety of EDG-7500 after a single and multiple doses in healthy adults Learn about how EDG-7500 is tolerated after a single and multiples doses in healthy adults Evaluate the amount of EDG-7500 is in the blood and urine after single and multiple doses in healthy adults Evaluate the effect of a meal on the amount of EDG-7500 that is in the blood in healthy adults Evaluate whether the amount of EDG-7500 in the blood is similar... Read More
Gender:
All
Ages:
Between 18 years and 59 years
Trial Updated:
02/26/2024
Locations: Celerion, Tempe, Arizona
Conditions: Healthy Subjects
Register for Updates
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
NCT05818085
Recruiting
This is a multicenter, randomized, double-blind, Phase 2b/3 study to evaluate the efficacy and safety of ABP-671. Part 1 of the study will compare the efficacy and safety of different doses and regimens of ABP-671 with placebo and allopurinol. Part 2 of the study will compare the dosing regimen(s) of ABP-671 selected from Part 1 with placebo in participants who have not been enrolled for Part 1.
Gender:
All
Ages:
Between 19 years and 69 years
Trial Updated:
02/08/2024
Locations: Alliance for Multispecialty Research, Tempe, Arizona
Conditions: Gout
Register for Updates
A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
NCT06000410
Recruiting
This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the knee.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Fiel Family & Sports Medicine, Tempe, Arizona
Conditions: Knee Osteoarthritis
Register for Updates
Priming Expectations and Motor Learning With tDCS
NCT06039605
Recruiting
The purpose of this study is to test if priming expectations of transcranial Direct Current Stimulation (tDCS) can improve the efficacy of tDCS in enhancing motor learning.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Arizona State University, Tempe, Arizona
Conditions: Expectations, Motor Learning
Register for Updates